Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590404 · ClinicalTrials.gov registry record · Phase 3
Metabolism Informed Smoking Treatment: The MIST RCT
A Phase 3 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
NCT04590404 is a Phase 3 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 606 participants.
The verdict
NCT04590404, a Phase 3 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
Study Summary
This phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.
Interventions
- DRUG Varenicline
- DRUG Nicotine Replacement Therapy
- BEHAVIORAL Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.
- OTHER Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04590404
The ClinicalTrials.gov registry entry for NCT04590404 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Varenicline is the first listed.
NCT04590404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04590404 about?
NCT04590404 is a clinical study titled "Metabolism Informed Smoking Treatment: The MIST RCT". This phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.
What is the current status of trial NCT04590404?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2020-11-17. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT04590404?
The interventions under investigation include: Varenicline (DRUG), Nicotine Replacement Therapy (DRUG), Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach. (BEHAVIORAL), Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy) (OTHER).
Who is sponsoring clinical trial NCT04590404?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.